SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems-Trading Strong Earnings Growth and Momentum
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jenna who wrote (3882)2/6/2001 11:32:18 AM
From: Jenna  Read Replies (2) of 6445
 
MEDX early trigger on premarket news ---> Medarex Licensee Files Antibody-Based Therapy IND >MEDX

DJ Medarex Licensee IND Filing-2:Treats Inflammatory Disease

PRINCETON, N.J. (Dow Jones)--Medarex Inc. (MEDX) licensee Centocor
Inc., a unit of Johnson & Johnson (JNJ), filed an investigational new
drug application with the Food and Drug Administration for the
investigation of a fully human antibody product in the treatment of
inflammatory disease.
In a press release Tuesday, the biopharmaceutical company said the
fully human antibody product was developed using its HuMAb-Mouse
technology.
Medarex develops monoclonal antibody and immunology technology to
discover and develop treatments for AIDS, cancer, and other diseases
and disorders.
-Jason Philyaw; Dow Jones Newswires; 201-938-5388
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News